Author Correction: Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

Michael D Crowther^#¹, Garry Dolton^#¹, Mateusz Legut¹, Marine E Caillaud¹, Angharad Lloyd¹, Meriem Attaf¹, Sarah A E Galloway¹, Cristina Rius¹, Colin P Farrell², Barbara Szomolay^{1

3}, Ann Ager^{1

3}, Alan L Parker⁴, Anna Fuller¹, Marco Donia⁵, James McCluskey⁶, Jamie Rossjohn^{1

3

7

8}, Inge Marie Svane⁵, John D Phillips², Andrew K Sewell^{9

10}

Affiliations

¹ Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
² Division of Hematology, University of Utah School of Medicine, Salt Lake City, UT, USA.
³ Systems Immunity Research Institute, Cardiff University, Cardiff, UK.
⁴ Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
⁵ Center for Cancer Immune Therapy, Herlev Hospital, Copenhagen University, Copenhagen, Denmark.
⁶ Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.
⁷ Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia.
⁸ Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
⁹ Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK. sewellak@cardiff.ac.uk.
¹⁰ Systems Immunity Research Institute, Cardiff University, Cardiff, UK. sewellak@cardiff.ac.uk.

^# Contributed equally.

Published Erratum

Michael D Crowther et al. Nat Immunol. 2020 Jun.

. 2020 Jun;21(6):695.

doi: 10.1038/s41590-020-0640-6.

¹ Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
² Division of Hematology, University of Utah School of Medicine, Salt Lake City, UT, USA.
³ Systems Immunity Research Institute, Cardiff University, Cardiff, UK.
⁴ Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
⁵ Center for Cancer Immune Therapy, Herlev Hospital, Copenhagen University, Copenhagen, Denmark.
⁶ Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.
⁷ Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia.
⁸ Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
⁹ Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK. sewellak@cardiff.ac.uk.
¹⁰ Systems Immunity Research Institute, Cardiff University, Cardiff, UK. sewellak@cardiff.ac.uk.

^# Contributed equally.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1.
Crowther MD, Dolton G, Legut M, Caillaud ME, Lloyd A, Attaf M, Galloway SAE, Rius C, Farrell CP, Szomolay B, Ager A, Parker AL, Fuller A, Donia M, McCluskey J, Rossjohn J, Svane IM, Phillips JD, Sewell AK. Crowther MD, et al. Nat Immunol. 2020 Feb;21(2):178-185. doi: 10.1038/s41590-019-0578-8. Epub 2020 Jan 20. Nat Immunol. 2020. PMID: 31959982 Free PMC article.